Halopropane

Halopropane (synonym FHD-3, trade name Tebron) is a halocarbon drug which was investigated as an inhalational anesthetic but was never marketed.[1] Its clinical development was terminated due to a high incidence of cardiac arrhythmias in patients, similarly to the cases of teflurane and norflurane.[2][3][4]

Halopropane
Clinical data
Trade namesTebron
ATC code
  • None
Identifiers
IUPAC name
  • 3-Bromo-1,1,2,2-tetrafluoropropane
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC3H3BrF4
Molar mass194.955 g·mol−1
3D model (JSmol)
SMILES
  • C(C(C(F)F)(F)F)Br
InChI
  • InChI=1S/C3H3BrF4/c4-1-3(7,8)2(5)6/h2H,1H2
  • Key:YVWGMAFXEJHFRO-UHFFFAOYSA-N

See also

References
  1. Webster NR, Galley HF (22 August 2013). Landmark Papers in Anaesthesia. OUP Oxford. pp. 70–. ISBN 978-0-19-163319-5.
  2. Acta anaesthesiologica Belgica. Acta Medica Belgica. 1974.
  3. Klein SL (1993). A glossary of anesthesia and related terminology. Springer-Verlag. ISBN 978-0-387-97831-4.
  4. Catcott EJ, Smithcors JF (1973). Progress in canine practice. American Veterinary Publications.



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.